Idioma:

Zevalin® (ibritumomab tiuxetan): After More Than a Decade of Treatment Experience, What Have We Learned?

Rizzieri, David

Critical reviews in oncology/hematology, 2016-09, Vol.105, p.5-17 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por

Título:
Zevalin® (ibritumomab tiuxetan): After More Than a Decade of Treatment Experience, What Have We Learned?
Autor: Rizzieri, David
Assuntos: Animals ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; B-Lymphocytes - drug effects ; Disease Progression ; Hematology, Oncology and Palliative Medicine ; Humans ; Ibritumomab tiuxetan ; Lymphoma, Non-Hodgkin - drug therapy ; Non-Hodgkin’s lymphoma ; Radioimmunotherapy ; Risk Factors ; Zevalin
É parte de: Critical reviews in oncology/hematology, 2016-09, Vol.105, p.5-17
Descrição: Highlights • Ibritumomab tiuxetan is a CD20-directed radiotherapeutic antibody. • It has demonstrated therapeutic efficacy in treating non-Hodgkin’s lymphoma. • There is uncertainty among clinicians regarding its use. • Since its approval, its treatment regimen has been simplified. • Benefits include single agent efficacy and avoidance of many AEs of chemotherapy.
Editor: Netherlands: Elsevier Ireland Ltd
Idioma: Inglês

Links

Voltar para lista de resultados